Iclusig back on US market; Ariad rises

Shares of Ariad Pharmaceuticals rose as high as 9% on 17 January after the company said Iclusig (ponatinib) was once again available in the US as a treatment for adults with refractory chronic myeloid leukemia (CML) and Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL) after a nearly three-month hiatus from the market.